TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - ASTRAZENECA Stock
Certificat
DE000SQ617K1
| Delayed Deutsche Boerse AG 02:12:43 2024-05-21 EDT | ||
| 3.61 EUR | +0.28% |
|
| Current month | -2.17% | ||
| 1 month | -25.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 3.61 | +0.28% |
| 24-05-20 | 3.6 | +0.84% |
| 24-05-17 | 3.57 | +1.42% |
| 24-05-16 | 3.52 | +0.57% |
| 24-05-15 | 3.5 | +6.06% |
Delayed Quote Deutsche Boerse AG
Last update May 21, 2024 at 02:12 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SQ617K |
| ISIN | DE000SQ617K1 |
| Date issued | 2023-01-05 |
| Strike | 15,141 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.28 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.79 € |
|---|---|
| Lowest since issue | 3.22 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
153.7
USD
Average target price
167.9
USD
Spread / Average Target
+9.24%
- Stock Market
- Certificates
- Certificat